Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Studies Needed on Impact of Cannabis Use on Puberty

By McMaster University | October 5, 2018

This is Constantine Samaan, centre, with second-year medical students Yung Lee and Sama Anvari.

McMaster University researchers say there is an urgent need for studies on the physical health effects of cannabis use, including its impact on puberty.

The call comes following a systematic review of existing literature that identified an absence of such research. The results of the review were published in Adolescent Health, Medicine and Therapeutics.

“While the effects of cannabis on neuropsychological and cognitive outcomes in children have been studied, there’s a need to understand the physical health effects of cannabis,” said lead author M. Constantine Samaan, an associate professor of the Department of Pediatrics at McMaster University and a pediatric endocrinologist with Hamilton Health Sciences’ McMaster Children’s Hospital.

“As puberty is a critical window of physical growth and development, it is critical to fully understand what impact cannabis consumption can have.”

Animals studies have shown that chronic cannabis use leads to delayed sexual maturation.

“With legalization, including here in Canada in October, the usage of cannabis among youth will likely increase and there is a need to understand how it will impact their physical health,” said Samaan. “While cannabis is not legalized for use by children under 18, this has not limited access by this group. A disruption during puberty can have lifelong implications on growth, metabolism and accumulation of bone mass.”

Samaan and his research team at McMaster set out to find studies on boys and girls under age 18 with exposure to recreational or medicinal cannabis. The use of cannabis included smoked, ingested and other modes of exposure to cannabis products. A minimum of 10 study participants were required for the study to be considered eligible for inclusion.

Using these criteria, the team reviewed several databases of medical and scientific journals as well as additional literature sources. The review identified 759 records. A total of 29 full-text papers were assessed for eligibility. However, all studies were excluded as they did not meet the eligibility criteria.

“Adequately powered longitudinal studies are urgently needed to provide pediatricians and other health care providers with high-quality information on the potential effects of cannabis on the physical health of children,” said Samaan. “If cannabis affects the physical health in children, clear approaches to prevention and screening for physical health effects are needed.”


Filed Under: Drug Discovery and Development

 

Related Articles Read More >

Portrait photo of Cardinal Health CFO and soon-to-be CEO Jason Hollar
Cardinal Health’s CFO to move up to corner office
CNS
The CNS drug development drum beat is getting louder
DeepMind
7 ways DeepMind’s AlphaFold is being used in life sciences
Biomarker
Bioanalytical method development and validation using Quanterix’s Simoa platform 

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50